370108-99-9
Chemical Structure
Vaxfectin
- CAS No.: 370108-99-9
- Formula:C81H163BrN3O10P
- Molecular Weight:1450.05
IUPAC Name: (R)-5-bromo-1-methyl-2-tritylisoindoline
InChIKey: LTOCXIVQWDANEX-UXCYUTBZSA-M
SMILES: NCCOP(OC[C@H](OC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)COC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)(O)=O.CCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC/C=C\CCCC.[Br-]
Biological Activity: Vaxfectin is a second-generation cationic lipid-based suspension that adjuvants effectively both pDNA and protein-based vaccines. Vaxfectin can boost the immune response against a range of pDNA-expressed pathogenic antigens in vivo. Vaxfectin can increase IgG titers and give rise to an IL-6 dependent enhancement of the humoral immune response without altering the Th1 type immune response. Vaxfectin can be studied for vaccine formulation[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vaxfectin | 99.94% | Vaxfectin is a second-generation cationic lipid-based suspension that adjuvants effectively both pDNA and protein-based vaccines. Vaxfectin can boost the immune response against a range of pDNA-expressed pathogenic antigens in vivo. Vaxfectin can increase IgG titers and give rise to an IL-6 dependent enhancement of the humoral immune response without altering the Th1 type immune response. Vaxfectin can be studied for vaccine formulation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sullivan SM, et, al. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46. [Content Brief]
- [2]. Hartikka, J., et al., (2001). Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine, 19(15-16), 1911–1923. [Content Brief]
- [3]. Reyes, L., et al., (2001). Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine, 19(27), 3778–3786. [Content Brief]
